Boron neutron capture therapeutics. Boron neutron capture therapeutics are pharmaceuticals used to deliver boron-10 to cancerous cells as part of boron neutron capture therapy (BNCT). Boron-10 atoms strongly absorb neutrons to form a metastable state of boron-11, which undergoes α-decay. By accumulating boron-10 in cancerous cells and subjecting the tumor to neutron radiation, high-energy α particles are selectively delivered only to the target cells. In order for BNCT to be effective, safe, and successful, therapeutic candidates must be non-toxic, must selectively accumulate in target tissue and not normal tissue, and must remain in target tissue while fading from the blood stream. As of 2023, the technology is available in Japan only, and even there few implementations have been reported.

Initial proposal and development 
Neutron capture therapy was first proposed in the literature in 1936 by Gordon L. Locher, who observed that isotopes with large neutron capture cross sections, such as boron-10, could be accumulated in cancerous tissue and bombarded with thermal neutrons to induce destruction of the cancerous cells. This idea was attractive because it had the potential to be more selective than traditional chemo- and radiotherapies. However, BNCT requires a neutron beam to act as a source of thermal neutrons and a suitable boron-delivery agent; neither was available at the time of Locher's suggestion. Therefore, it was not until the 1950s, when nuclear reactors were available to medical researchers, that Locher's proposal was put into practice.

Boron delivery agents

Requirements for boron delivery agents 
A BNCT therapeutic candidate must selectively accumulate in target tissue without significant uptake in normal tissue. If selectivity is low and boron accumulates in both, irradiation with thermal neutrons will cause significant damage to healthy tissue; if boron accumulates in neither, the treatment will be ineffective. Selectivity is quantified by the  tissue boron ratio, which compares the concentration of boron atoms in tumor cells with that in the patient's healthy cells. A large  tissue ratio (~3 or greater) is necessary. In addition, boron must remain in target tissue at significant concentrations (~20 μg/g) for long enough that concentration in the blood drops to low levels (generally several hours).

Early candidates 
Early work in the 1950s made use of widely available non-toxic boron compounds such as sodium borate (also known as borax) and boric acid. Sodium borate was used to treat nearly a dozen patients with BNCT through a collaboration between Massachusetts General Hospital and Brookhaven National Laboratory. The results were inconclusive and lack of success was blamed on the short lifetime of the tumor:normal tissue differential.

Seeking to improve selectivity through chemical modification, studies were performed to correlate lipid solubility with penetration of the blood-brain barrier in mice. It was determined that compounds with high solubility in benzene are more capable of penetrating the brain, and should thus be avoided as BNCT therapeutics. Based on this data, boron-10 enriched samples of p-carboxyphenylboronic acid (PCPB) and sodium decahydrodecaborate (Na2B10H10) were selected for BNCT at the Massachusetts Institute of Technology research reactor. The therapy was performed on eighteen patients before the realization that patients were receiving severe radiation damage to normal tissue ended the trial. Later analysis established the likely cause of death as radiation necrosis for at least nine patients, and the study has been described as a “total failure”. Radiation necrosis was attributed to fission of boron-10 atoms in the bloodstream, damaging adjacent blood vessels. PCPB and Na2B10H10 had been selected for their promising tumor:normal tissue differentials; however, the concentration of boron-10 in patients’ blood was not considered as significant a concern until after these results.

Second-generation boron delivery agents 

Building on the dodecaborane anion ([B12H12]2-) discovered in part by M. Frederick Hawthorne, Earl Muetterties et al. developed the monosubstituted derivative sodium borocaptate (BSH, Na2B12H11SH). While screening boron compounds for use in BNCT, it was discovered that BSH and other monosubstituted sulfhydryl boron hydride clusters accumulate in cancerous cells without lingering in the blood stream — exactly the properties needed for new BNCT therapeutics. It has been theorized that the thiol moiety present in BSH plays a role in the differing biological uptake properties between [B12H12]2- and BSH, though more research must be done to understand the relevant biochemistry.

Although clinical work with BNCT in the United States was paused for decades after the MIT reactor experiments, BNCT continued in Japan. Using BSH synthesized by the Shionogi pharmaceutical company, BNCT was used to treat over 200 patients by Hiroshi Hatanaka, Yoshinobu Nakagawa, and their colleagues. The success and efficacy of the Hatanaka/Nakagawa work has been debated, with some arguing that there was no significant improvement in patient outcomes; others argue, however, that critics are focusing on small subsamples of the patient population, and are not taking into account that neutron beams accessible to Hatanaka were much less powerful than those at Brookhaven and at MIT. Further studies have been carried out in the Netherlands and the Czech Republic, and BSH continues to be tested for BNCT.

First synthesized in 1958 by Snyder et al., boronophenylalanine (BPA) and its more water-soluble fructose complex (BPA-F) were not initially acknowledged as potential BNCT therapeutics. In the 1970s, however, researchers in Japan proposed that BPA could be used to target malignant melanomas with BNCT. Previous work on BNCT had only targeted cancers of the brain, using the blood-brain barrier to improve tumor:normal tissue differentials. Researchers argued, however, that similarities between BPA and the precursor amino acids to melanin meant that melanomas may selectively accumulate BPA. Clinical trials began again in the United States in the 1990s at Brookhaven and at MIT using BPA, both for melanomas and glioblastomas. In contrast with the Japanese BSH trials, higher-energy epithermal neutrons were used in place of thermal neutrons, allowing for deeper penetration into the brain without the need for neurosurgery during treatment. Further trials with BPA have been carried out in Finland, the Netherlands, Sweden, Taiwan, and Japan. In some trials, both BPA and BSH were used as the delivery agent, and some studies have tested the effectiveness of BNCT in conjunction with traditional chemo- and radiotherapies. The primary flaw with both BSH and BPA/BPA-F seems to be heterogeneity in distribution of boron-10 throughout the tumors.

Third-generation boron delivery agents 
Despite some successes with BSH and BPA, broad variability in tumor uptake and heterogeneous distribution within tumors have led researchers to pursue updated alternatives. Third-generation boron delivery agents are marked by inclusion of a specific chemical tumor-targeting moiety, often borrowed from those established in chemotherapy, linked to a boron-carrying compound. These targeted drug delivery systems are designed to bind the delivery agent to chemical sites found in tumor cells, rather than relying on secondary properties such as hydrophilicity; the use of BPA to target melanomas was an early example. Examples of compounds derivativized for BNCT include "peptides, proteins, antibodies, nucleosides, sugars, porphyrins, liposomes and nanoparticles." While animal and in vitro studies have shown potential, no third-generation boron delivery agent has yet been used in a clinical trial.

References 

Wikipedia Student Program
Cancer treatments
Boron compounds